Samplix raises €3M in new capital as WLan leads €25M balance-sheet restructuring
What's the deal? Danish startup SamplixDealroom has a profile for this one. Try Dealroom → has raised €3 million in new capital as part of a €25 million first closing led by WLanholding GmbHDealroom has a profile for this one. Try Dealroom →. The round brings in €22 million through the conversion of existing shareholders' convertible bonds and remains open toward a €30 million target.
What does Samplix do? It provides droplet microfluidics technology for functional single-cell analysis in the biopharmaceutical sector. Its Xdrop platform lets researchers identify and recover cells producing antibodies with a desired biological function, running on flow cytometry and cell-sorting equipment many labs already own.
What's the money for? Samplix said the financing strengthens its balance sheet and supports the commercial expansion of Xdrop for antibody discovery and biotherapeutic development. As part of the deal, Werner Lanthaler, founder and managing director of WLan and former chief executive officer of Evotec, will join the board within the next year.
Why now? The backing comes at a precarious moment. Samplix's 2025 accounts reported a net loss of US$8.14M, negative equity of US$16.7M, and an auditor's warning of "considerable doubt" over the company's ability to continue, making the capital as much about survival as expansion.
Between the lines: The €3 million in genuinely new money is modest, sitting around the 25th percentile for deals of its kind. Most of the €25 million is a restructuring that converts debt into equity rather than fresh cash.
What could go wrong? The announcement offers no commercial traction figures. "This investment is a further validation of the value our Xdrop platform brings to the antibody discovery community," said chief executive Henrik Pfundheller — but the key test is whether the financing converts into customer adoption and revenue.
The signal: Single-cell functional screening is drawing investor interest; UK peer LightcastDealroom has a profile for this one. Try Dealroom → raised $27 million in April 2026 for a platform with antibody-discovery applications. Samplix has a credible market and differentiated technology, but its finances show how hard commercialization remains for life-science tools startups in a cautious funding environment.
Read more: international-biopharma.com
Image credit: Generated with Gemini
